Growth Metrics

Gilead Sciences (GILD) Cash from Investing Activities (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 196.46%
Dec 31, 2025 -329.74%
Sep 30, 2025 79.82%
Jun 30, 2025 -409.88%
Mar 31, 2025 -84.44%
Dec 31, 2024 68.31%
Sep 30, 2024 -131.27%
Jun 30, 2024 86.09%
Mar 31, 2024 -203.58%
Dec 31, 2023 -217.47%
Sep 30, 2023 52.59%
Jun 30, 2023 41.53%
Mar 31, 2023 -120.27%
Dec 31, 2022 47.41%
Sep 30, 2022 -131.49%
Jun 30, 2022 71.21%
Mar 31, 2022 -284.89%
Dec 31, 2021 -18.80%
Sep 30, 2021 59.45%
Jun 30, 2021 71.74%
Mar 31, 2021 77.25%
Dec 31, 2020 -3,212.55%
Sep 30, 2020 94.60%
Jun 30, 2020 -1,360.17%
Mar 31, 2020 -179.81%
Dec 31, 2019 123.41%
Sep 30, 2019 70.13%
Jun 30, 2019 -2,425.82%
Mar 31, 2019 -108.92%
Dec 31, 2018 35.06%
Sep 30, 2018 -61.36%
Jun 30, 2018 20.37%
Mar 31, 2018 143.47%
Dec 31, 2017 -373.79%
Sep 30, 2017 50.21%
Jun 30, 2017 -1,483.06%
Mar 31, 2017 111.48%
Dec 31, 2016 31.71%
Sep 30, 2016 -19.28%
Jun 30, 2016 -55.71%
Mar 31, 2016 13.49%
Dec 31, 2015 41.76%
Sep 30, 2015 -17.85%
Jun 30, 2015 -54.50%
Mar 31, 2015 -467.65%
Dec 31, 2014 47.40%
Sep 30, 2014 -58.11%
Jun 30, 2014 -202.48%
Mar 31, 2014 -174.27%
Dec 31, 2013 2,798.77%
Sep 30, 2013 85.52%
Jun 30, 2013 86.38%
Mar 31, 2013 -912.50%
Dec 31, 2012 109.68%
Sep 30, 2012 18.41%
Jun 30, 2012 94.09%
Mar 31, 2012 -341.94%
Dec 31, 2011 5,628.31%
Sep 30, 2011 82.90%
Jun 30, 2011 -56.40%
Mar 31, 2011 26.34%
Dec 31, 2010 70.75%
Sep 30, 2010 -249.43%
Jun 30, 2010 187.29%
Mar 31, 2010 -168.75%
Dec 31, 2009 6.79%
Sep 30, 2009 59.87%
Jun 30, 2009 -223.76%